PMID- 38509849
OWN - NLM
STAT- Publisher
LR  - 20240321
IS  - 2055-5822 (Electronic)
IS  - 2055-5822 (Linking)
DP  - 2024 Mar 21
TI  - Analysis of the serum levels of RIP3 and Drp1 in patients with heart failure.
LID - 10.1002/ehf2.14771 [doi]
AB  - AIMS: As necroptosis involving receptor-interacting protein kinase 3 (RIP3) and 
      dynamin-related protein 1 (Drp1)-mediated signalling is a crucial mechanism of 
      cell loss in heart failure (HF), we aimed to determine the potential diagnostic 
      use of these molecules. METHODS AND RESULTS: The serum samples of the healthy 
      subjects (n = 8) and patients with HF with reduced ejection fraction (n = 31), 
      being subdivided according to the aetiology and New York Heart Association (NYHA) 
      class, were used to measure RIP3 and Drp1 levels by enzyme-linked immunosorbent 
      assay. Although the serum levels of Drp1 in the patients with HF were comparable 
      with those seen in healthy individuals, we found a trend of increase in the 
      levels of RIP3 (P = 0.0697) in the diseased group. These changes were unlikely 
      dependent on the HF aetiology or NYHA class. The circulating RIP3 correlated with 
      neither the main parameters assessing cardiac function (left ventricular ejection 
      fraction, left ventricular end-diastolic diameter, and N-terminal pro-brain 
      natriuretic peptide) nor the marker of inflammation (C-reactive protein). 
      CONCLUSIONS: In this pilot study, findings on serum RIP3 supported the importance 
      of necroptosis in HF pathomechanisms. The potential diagnostic use of circulating 
      RIP3, unlike Drp1, as an additional biomarker of HF has also been indicated; 
      however, further large studies are needed to prove this concept.
CI  - (c) 2024 The Authors. ESC Heart Failure published by John Wiley & Sons Ltd on 
      behalf of European Society of Cardiology.
FAU - Jarabicova, Izabela
AU  - Jarabicova I
AD  - Faculty of Pharmacy, Department of Pharmacology and Toxicology, Comenius 
      University, Bratislava, Slovak Republic.
FAU - Horvath, Csaba
AU  - Horvath C
AD  - Faculty of Pharmacy, Department of Pharmacology and Toxicology, Comenius 
      University, Bratislava, Slovak Republic.
FAU - Chudy, Martin
AU  - Chudy M
AD  - Faculty of Medicine, Department of Cardiology, Comenius University and National 
      Cardiovascular Institute, Bratislava, Slovak Republic.
FAU - Goncalvesova, Eva
AU  - Goncalvesova E
AD  - Faculty of Medicine, Department of Cardiology, Comenius University and National 
      Cardiovascular Institute, Bratislava, Slovak Republic.
FAU - Adameova, Adriana
AU  - Adameova A
AD  - Faculty of Pharmacy, Department of Pharmacology and Toxicology, Comenius 
      University, Bratislava, Slovak Republic.
AD  - Centre of Experimental Medicine, Institute for Heart Research, Slovak Academy of 
      Sciences, Bratislava, Slovak Republic.
LA  - eng
GR  - VEGA 1/0016/20/Scientific Grant Agency of the Ministry of Education, Science, 
      Research and Sport of the Slovak Republic/
GR  - APVV-15-0607/Slovak Research and Development Agency/
GR  - APVV-20-0242/Slovak Research and Development Agency/
PT  - Journal Article
DEP - 20240321
PL  - England
TA  - ESC Heart Fail
JT  - ESC heart failure
JID - 101669191
SB  - IM
OTO - NOTNLM
OT  - Dynamin-related protein 1
OT  - Heart failure
OT  - Necroptosis
OT  - Receptor-interacting protein kinase 3
EDAT- 2024/03/21 06:43
MHDA- 2024/03/21 06:43
CRDT- 2024/03/21 03:45
PHST- 2024/01/31 00:00 [revised]
PHST- 2023/12/05 00:00 [received]
PHST- 2024/03/06 00:00 [accepted]
PHST- 2024/03/21 06:43 [medline]
PHST- 2024/03/21 06:43 [pubmed]
PHST- 2024/03/21 03:45 [entrez]
AID - 10.1002/ehf2.14771 [doi]
PST - aheadofprint
SO  - ESC Heart Fail. 2024 Mar 21. doi: 10.1002/ehf2.14771.